期刊文献+

阿托伐他汀降脂治疗对纤溶系统及血小板的影响 被引量:7

Effect of atorvastation On Fibrinolysis System and Platelets
下载PDF
导出
摘要 目的 :了解阿托伐他汀降脂治疗对纤溶系统及血小板的影响。方法 :选择高脂血症患者 ,给予阿托伐他汀治疗 ,测定服药前后血脂、血浆中纤溶酶原激活剂 (t -PA)、纤溶酶原激活物抑制剂 (PAI - 1)及血小板α颗粒膜蛋白 (GMP - 14 0 )的含量 ,并与正常人对照。结果 :治疗前高脂血症患者的血浆t -PA含量明显低于正常人 ,而血浆PAI - 1及GMP - 14 0含量高于正常人 ,经降脂治疗后血浆t-PA含量上升 ,而血浆PAI - 1及GMP - 14 0含量下降 ,接近正常。结论 :阿托伐他汀可明显降低高脂血症患者的血脂水平 ,并且有一定的改善纤溶系统功能及抑制血小板激活的作用。
作者 沈敏 李兰荪
出处 《中国现代医学杂志》 CAS CSCD 2003年第17期104-106,共3页 China Journal of Modern Medicine
  • 相关文献

参考文献7

  • 1Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P - selectin and P-selectin ligand. Thromb Haemost, 1995;74:224--227.
  • 2Salsela O, Rilkin DH. Cell - associated plasminogen activation: regulation and Physiological functions. Ann Rev Cell Biol,1998; (4) :93.
  • 3Yamaoto A, Harada - Shiba M, Kawaguehi A, et al. Apheresis technology for prevention and regression of atherosclerosis. Ther Apher, 2001 ;5(4):221 --225.
  • 4Roserkson RS, Tangney CC. Antiathemthrombotic properties of statins: implications, for cardiovascular event reduction. JAMA,1998;279(20) : 1643--1650.
  • 5Koh KK. Effects of statins on vascular wall : vasomotor function inflammation, and plaque stability. Cardiovasc Res, 2000;47(4) :648--657.
  • 6Bermudez EA, Ridker PM. Perspectives: C- reactive protein,statins, and the primary prevention of atherosclerotic cardiovascular disease. Prey Cardiol,2002 ; 5 ( 1 ) : 42-- 46.
  • 7Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis:from laboratory evidence to clinical application.Ital Heart J ,2001 ;2(11):796-800.

同被引文献54

  • 1马绍椿,徐新,唐良秋,叶小兰,肖全华.阿托伐他汀对血脂正常的稳定性心绞痛患者的抗心肌缺血作用[J].中国医师杂志,2004,6(7):1002-1003. 被引量:4
  • 2于安忠,姚卫东,李继福,唐书义.冠状动脉介入治疗致心肌微损伤的研究进展[J].中国综合临床,2004,20(12):1147-1148. 被引量:4
  • 3公英子,赵翠萍.氟伐他汀治疗对不稳定心绞痛患者CRP、PAI-1、Fib的影响[J].中国现代医学杂志,2005,15(17):2644-2646. 被引量:2
  • 4各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33024
  • 5Sehayek E, Butbul E, Avner R, et al. Enhanced cellular metabolism of very low density lipoprotein by simvastatin : a novel mechanism of action of HMG-CoA reductase inhibitors . Eur J Clin Invest, 1994,24 : 173-178.
  • 6Kaesemeyer WH, Caldwell RB, Huang JZ, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol, 1999, 33:234-241.
  • 7Ikeda U, Shimpo M, Ohki R. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascularendothelial cells. Hypertension, 2000, 36 : 325-329.
  • 8Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atcrvastain on early recurrent ischemic events in acute corronary syndromes the MIRACLE study. Arandomized controlled trial. JAMA, 2001,285( 1711 ) : 1718-1725.
  • 9Furberg CD, Byington RP, Crouse JR, et al. Pravastain lipids, and atherosclerosis the carotid arteries (PLACII. Am J Cardiol, 1998,75:455-459.
  • 10Pederson JR, Olsson AG, Faergeman V, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simavastatin Survival Study (4s)[J]. Circulation ,1998,97:1453-1460.

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部